Author Archives: admin


Lung fibrosis? Stem cell therapy holds promise – The Hindu

A team of scientists from the UNC School of Medicine and North Carolina State University (NCSU), U.S. have developed promising research towards possible stem cell treatment for several lung conditions, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis, all of which are known to be fatal conditions. In the journal Respiratory Research, the scientists demonstrated that they could harvest lung stem cells from people using a relatively non-invasive, doctors office technique. They were then able to multiply the harvested lung cells in the lab to yield enough cells sufficient for human therapy.

In a second study, published in the journal Stem Cells Translational Medicine, the team showed that in rodents they could use the same type of lung cell to successfully treat a model of IPF a chronic, irreversible, and ultimately fatal disease characterised by a progressive decline in lung function. These diseases of the lung involve the build-up of fibrous, scar-like tissue, typically due to chronic lung inflammation. As this fibrous tissue replaces working lung tissue, the lungs become less able to transfer oxygen to the blood. Patients ultimately are at risk of early death from respiratory failure. In the case of IPF, which has been linked to smoking, most patients live for fewer than five years after diagnosis.

Read this article:
Lung fibrosis? Stem cell therapy holds promise - The Hindu

From one cell to billions: Juan Carlos Izpisa Belmonte studies all stages of life – The San Diego Union-Tribune

Salk Institute researcher Juan Carlos Izpisa Belmonte appears to be everywhere in the field of stem cells and regenerative medicine.

He has helped to invent a new kind of stem cell, performed groundbreaking research in growing human organs in animals and demonstrated in mice how to reverse signs of aging.

In addition, his research has produced mini-kidney organoids from stem cells, pointed to a novel way of preventing mitochondrial disease and most recently, helped to prove that a genetic defect can be efficiently repaired in human embryos. The production of mini-kidneys was chosen by Science magazine in 2013 as a runner-up for its Breakthrough of the Year honor.

Izpisa Belmonte tackles the most difficult problems from conception to old age, including aging itself. Its an interest carried from his youth in Spain, when he became fascinated by the regenerative powers of some animals, powers he would like to confer on humanity.

I am a basic developmental biologist at heart, he said by email from Spain, where he performs research in addition to his Salk lab in La Jolla.

My passion is to study and understand the development of an organism the process by which, after conception, a single cell divides and generates billions of cells and a human being is created. This includes the study of degeneration and regeneration of our cells and organs.

Evan Snyder, a prominent stem cell researcher at the Sanford Burnham Prebys Medical Discovery Institute who has known Izpisa Belmonte since 2003, said: He knows what will be the important questions to answer. The very fact that he can answer them so quickly after theyve been posed means hes been thinking about them already.

Izpisa Belmonte maintains a huge variety of projects in collaboration with colleagues in Europe, the United States and Asia. Snyder and other peers said he succeeds by harnessing imagination with good organizational skills and persistence.

And somehow, while succeeding in the highly competitive field of science, Izpisa Belmonte maintains a courtly, Old World grace and charm, and even humility.

I would say Juan Carlos is one of the most gentle, self-effacing, collaborative, genuinely nice people Ive ever met, Snyder said.

In one instance, Snyder recalled witnessing Izpisa Belmonte encounter a scientist he had beaten to the punch with a discovery. He apologized for having done that and simply said the work just went quicker than expected, Snyder said. It was one of the sweetest things Ive ever seen.

Jun Wu, a Salk researcher in Izpisa Belmontes lab, co-authored the recent study on repairing genetic defects in human embryos. Wu said his first meeting with Izpisa Belmonte was memorable because of that tact and consideration, along with helpful advice.

Hes a good listener, Wu said. He listened to what I had to say about my project. And then he gave me some suggestions. He gave me a lot of freedom to think in my own way, but at the same time he gave me the proper guidance to where I should go.

In other words, Izpisa Belmonte maintains an open-mindedness as a person and scientist, Wu said. Many scientists specialize in particular areas, using a fixed pattern of investigation. Izpisa Belmonte encourages his researchers to explore different paths, and if that path turns out to be wrong, to think about it and learn from that experience.

As scientists, we need to be critical of ourselves, while at the same time we need to be open to the possibility that other people criticizing or saying negative things about us could be right, Wu said.

Izpisa Belmonte was born in 1960 in the small town of Helln in southwestern Spain.

I come from a modest, poor family, he said. My grandfather was a baker, my father left home when I was little and my mother worked in whatever she could to feed me and my brothers.

I left school very early to help earn money for my family by picking almonds, grapes, etc., during harvest time and working as a bellboy before I was even 14, the legal age at that time in my country to start working.

His chief role model was his mother, who taught me the spirit of hard work and fairness, he said.

I remember I used to read a lot, first comics and later on more serious things, mostly classical philosophy. I always remember having a special interest and curiosity to know more about the meaning of life.

But while reading philosophy, Izpisa Belmonte also entertained more worldly fantasies, particularly about being a soccer player.

I even managed to play on a professional soccer team, he said. However, just when I thought that I had a bright future as a player, the coach sat me on the substitutes bench for several months and I realized that perhaps I was not good enough. I then decided that my footballing dream was over and I decided to go back to school. I think the soccer coach that didnt let me play was very decisive for my scientific career.

For that career, Izpisa Belmonte traveled to the big city, Valencia, to enroll in college. Uncertain of his academic path, he chanced on pharmacology.

I am very satisfied with my decision, he said. What I learned there, especially in the subjects of biology and chemistry, was key for me to dedicate my life afterward to try to understand how life, a living organism, is generated.

He earned a series of degrees, including a Ph.D. from the University of Valencia and the University of Bologna in Italy. He did postdoctoral work in Germany and at UCLA.

As a young scientist, he focused on his first big question: How is an embryo formed from one cell, and how does it develop into a complete organism? From that question came early discoveries, including key genes and mechanisms for the formation of organs and limbs, and how they are arranged in the body.

Izpisa Belmonte arrived at the Salk Institute for Biological Studies in 1993, and is now a professor in the Gene Expression Lab. In 2011, he was named as the first holder of the Roger Guillemin Chair, endowed with $3 million by San Diego philanthropists Irwin and Joan Jacobs.

Guillemin, also a Salk professor, received the 1977 Nobel Prize for physiology or medicine.

Guillemin recalls that when he met Izpisa Belmonte, he was struck by the mans purposeful demeanor.

Immediately I knew that this was a very serious young man, that he knew what he was talking about, Guillemin said. From what I understand of the science, hes at the very frontier of whats possible in molecular biology.

In the most recent research, Izpisa Belmonte was one of five senior authors of a study that demonstrated in human embryos that a genetic defect can be corrected. The defect causes a heart disease called hypertrophic cardiomyopathy. It can cause sudden death in apparently healthy people, such as young athletes.

While the embryos werent allowed to develop for more than several days, the study provided proof of principle that such defects can be fixed right around the time of conception.

This is the type of problem that modern molecular biology can look into and become proficient at affecting, Guillemin said.

Last year, Izpisa Belmonte received a grant of at least $2.5 million over five years to study how to generate functional primate organs in pigs, using stem cell technologies he and colleagues developed.

The grant was a Pioneer Award from the National Institutes of Health, given to individual scientists of exceptional creativity who propose pioneering and highly innovative approaches with the potential to produce an unusually high impact on biomedical or behavioral research.

Getting organs of one species to grow in another is difficult, but Izpisa Belmonte said if tissues are implanted at the right time and under the right conditions, a host animals body could provide the proper signaling needed to direct organ development.

Early this year, a team including Izpisa Belmonte reported success in creating a rat-mouse mixture that grew functional organs. They did this by disabling a single gene in single-cell mouse embryos that was needed for development of a specific organ. They then added rat stem cells, which took the place of the vacant mouse organ. This method yielded functional rat eye, heart and pancreas tissue in the mouse.

They tried a somewhat similar experiment in pigs, which proved more difficult. Pigs gestate for about three months and three weeks, while human pregnancies extend for nine months. By experimenting with different kinds of human stem cells, the team finally produced human-pig embryos that grew for about three weeks before they were killed.

While both human and pig cells were present in the embryos, the rate of human cell survival was low. The research team is trying to overcome this challenge by selectively disabling genes in the pig embryos, as they did in the mouse embryos.

Along with the technical challenges, ethical considerations must be met.

For example, allowing human brain tissue to develop in a pig might produce an animal with a partially human consciousness. Thats not likely in the pig-human experiments, because there was no sign that the human cells ever got into the pig brains to begin with.

Izpisa Belmonte downplays his role in the various groundbreaking projects, preferring to give most of the credit to those in his lab.

My role is perhaps the least important of all in our team, he said. I am very fortunate to have many talented junior and senior research scientists working with me. They all have different backgrounds and expertise, not just scientifically, but also culturally, since many of them come from abroad. This has enabled us to think about a problem from different angles and see things more comprehensively.

Equally important, he said, is the scientific and administrative support at the Salk Institute, a true scientific paradise.

I have visited many other institutions and I feel that there is no place that can compare. Most of our best ideas and projects come through interactions with my faculty colleagues and learning from the incredible discoveries and conceptual advances they produce.

Most of his friends come from the world of science, Izpisa Belmonte said, expressing some regret that he let science interfere with some of his relationships.

I had a very close friend who died very young, and I didnt have many other friends in my youth, he said. Friendships are like plants; they need to be fertilized from time to time to grow well, and unfortunately, I did not dedicate time to this.

It was also difficult because I moved from country to country very often during my scientific pursuits. Now I have some colleagues that, after working with them, have become good friends.

Human embryo gene editing endorsed for research

With embryo gene editing a reality, humanity enters a new era

Controversial milestone: Scientists genetically modify human embryos for first time, reports say

'Second genetic code' edited in stem cells to study disease-causing changes

New stem cell invented that can grow into any tissue in the body

Salk scientist wants to solve transplant shortage by growing organs in animals

How do we age?

New stem cell may be key to human organs in animals

Go here to read the rest:
From one cell to billions: Juan Carlos Izpisa Belmonte studies all stages of life - The San Diego Union-Tribune

Got allergies? Scientists may have finally pinpointed the cells that trigger reactions – Science Magazine

Researchers have identified the cells that unleash allergy symptoms such as sneezing.

Imgorthand/iStockphoto

By Mitch LeslieAug. 2, 2017 , 2:00 PM

If you sneeze your way through ragweed season or need a restraining order against your neighbors cat, researchers finally know what part of your immune system you should blame. A new study nails down the specific group of cells that orchestrates allergic reactions, a result that could help scientists determine not only why some people have allergies, but also how to block them.

Its exciting for those of us who are looking at potential ways to treat allergic diseases, says Thomas Casale, an allergist and immunologist at the University of South Florida in Tampa who wasnt connected to the study.

Allergies stem from mistaken identity, when some of our immune cells respond to benign substancesknown as allergensthat include pollen, mold spores, and certain foods. Researchers know that the culprits that touch off allergic symptoms belong to a group of T cells known as TH2 cells. But not all TH2 cells are culpable. Some guard us against parasites and other invaders. Sorting the beneficial TH2 cells from the rogues has proveddifficult, however.

In the new study, researchers led by T cell biologist Erik Wambre and immunologist William Kwok of the Benaroya Research Institute at Virginia Mason in Seattle, Washington, obtained blood samples from patients who were sensitive to pollen from alder trees, a common cause of winter and spring allergies. An allergic patients TH2 cells recognize and respond to an allergen because they carry receptors, proteins that match allergen molecules. To tag immune cells carrying receptors for alder pollen, the team added customized fluorescent proteins known as MHCII tetramers to the patients blood samples.

Along with receptors, TH2 cells are dotted with marker proteins. Like sports fans wearing their favorite teams jersey, immune cells proclaim their identity with these marker proteins. The researchers analyzed the tagged cells to determine their combination of markers. Compared with other TH2 cells, one group sported more copies of two marker proteins and fewer copies of four others. Although none of the proteins was exclusive to the cells, together they provided a signature for this clique of TH2 cells, which the researchers dubbed TH2A cells. T cells can sometimes shift identifies, but the researchers found that TH2A cells remained distinct, even after several cellular generations. When these cells are born, they are born to be pathogenic, Wambre says.

As they report online today in Science Translational Medicine, Wambre, Kwok, and colleagues found that the cells were abundant in the blood of patients with allergies to a variety of triggers, including grass pollen and house dust mites. But they were absent from the blood of people who werent sensitive. The team also tested patients undergoing an experimental treatment called oral immunotherapy to alleviate their peanut allergies. Over about 20 weeks, the participants receive larger and larger doses of allergy-inducing peanut proteins, and this repeated exposure eventually allows them to tolerate peanuts.

We saw a dramatic decrease in TH2A cells after the success of the treatment, Wambre says. The number of these cells in the patients that reacted to peanuts fell by about 90%. Kwok says that the evidence he and his colleagues have accumulated suggests that people with allergies make this specific subset of T cells that probably lead to allergic symptoms.

The work could ultimately benefit patients through new treatments and better ways to monitor the disease, says immunologist Andrew Luster of Massachusetts General Hospital in Charlestown. For example, he notes, scientists could assess trials of oral immunotherapywhich attempts to quell patients allergies with edible doses of food allergensby tracking which treatments were eliminating TH2A cells. Another option, Kwok adds, is that if researchers can determine what molecular signals steer certain T cells to become TH2A cells, they may be able to develop ways to prevent formation of the cells. If researchers succeed in that, they might also prevent a lot of sniffling and scratching.

Read this article:
Got allergies? Scientists may have finally pinpointed the cells that trigger reactions - Science Magazine

Studying Astronaut Health Could Benefit Medicine for All – TrendinTech

Ever since the Apollo missions, the health of astronauts have suffered long after their time in space was over. From reduced bone density to weakened muscles to cardiovascular damage, low gravity environments take a toll on the human body. Many of the astronauts ailments closely resemble conditions suffered by those of advanced age, from back pain to osteoporosis, the research of low gravity healthcare goes beyond astronauts alone.

Fortunately, the University of California at San Francisco (UCSF) researchers are working to understand, develop protocols and treatments that can help astronauts and the general population.

Even with exercise routines developed to maintain muscle mass and bone density, many astronauts complain of back pain lasting for years after their low gravity exposure. Dr. Jeffrey Lotz of UCSF has been studying the vertebrae of astronauts to understand the source of the problem and was surprised by his results.

Although he thought the cause of pain would be water retention in disks, what would normally be pressed out of them by bone compression due to gravity, instead he found a deterioration in the muscles that support the back bone called the multifidus muscles.

Now, he is working in coordination with NASA to design a series of exercises that target these muscles while also considering the limitations of room on a spaceship and low gravity.

The exercises are not for muscle health alone but include improving bone health. However, as Dr. Daniel Bickle discovered in mouse studies exercise alone is not enough to maintain bone density in space.

According to his studies, the low gravity environment disturbs the signal process between osteoclasts and osteoblasts. In normal bone processes, bone is reinforced when damaged or put under the repetitive stress of walking around in Earths gravity. With those stressors gone in low-gravity, osteocyte cells in bone tissue detect decreased stress in certain areas, then sends an activation signal to reabsorb the extra bone tissue thats no longer need to the osteoclasts. Once the work of the osteoclasts is done, another signal is sent to osteoblasts, which then rebuilds necessary bone.

Because the signal interruption is occurring in the later stage of the process, between the osteoclasts and osteoblasts, bone continues being absorbed but does not get rebuilt while in space.

Astronauts with only six months spent on ISS have a reduced bone density loss of six to nine percent, a loss equal to that typically seen annually in postmenopausal women. Although the astronauts may regain the bone density after a year spent in normal gravity, the bone material is redistributed in such a way that their skeletal structures resemble that of an older adult.

Dr. Bickle thinks that further study into why this happens would not only aid astronauts and deep space travel but could also unlock treatments for osteoporosis.

Another factor leading to reduced bone density in astronauts is radiation exposure, but Dr. Bernard Halloran has discovered an interesting solution for this cause of bone loss.

Although it is unclear why Dr. Hallorans experiments with mice have proven that plum powder reduces the loss of bone due to radiation exposure. While further study is needed to concentrate the mysterious active ingredient into pill form, it is a promising discovery for low-gravity healthcare.

Perhaps the most detrimental of all the effects of spaceflight, and aging is the effect on the cardiovascular system. Over the years, Dr. Marlene Grenon has studied the effects of microgravity on astronauts, who often suffer from circulatory issues after returning to Earth and increases the risk of heart attack as they age.

Dr. Grenon and colleagues, Dr. Sonja Schrepfer and Dr. Tobias Deuse, have found multiple factors influenced by the low gravity environment of space, including gene expression, cell function interference, and thinning vascular walls, which contribute to the declining cardiovascular health of astronauts. Similar issues are evident in normal gravity cardiovascular disease sufferers.

Although not a problem on ISS, as astronauts return to normal life on Earth, the effect on their health is detrimental(damaging) and long term. But Dr. Schrepfers team has discovered a molecule that may stop the thinning of vascular walls and hope to begin human trials soon.

Additionally, Dr. Schrepfer will be studying the effects of space on the human immune system similar to the work done by Dr. Millie Hughes-Fulford, whos been studying the subject since 2003.

Currently, Dr. Hughes-Fulford has been studying gene expression in T-cells. Her studies have found that in low gravity five different miRNAs (microRNA), normally responsible for activating the genes of T-cells, were not functioning. These alterations, normally seen in the elderly over a period of 30 years, starting in astronauts, typically at the height of health, after only 30 minutes in space.

So far, the only cell function researchers can find that is not negatively affected by time spent in space is the process by which DNA repairs itself. Dr. Faith Karouia of USCF and Dr. Honglu Wu of NASAs Johnson Space Center, have studied fibroblast cells from micro gravity environments compared to Earth bound cells and found no change despite the change in gravity or radiation.

Although more data is needed for a full conclusion, scientists hope the discovery can aid research into how cancer cells survive and self-heal through radiation treatment as well as help bolster astronaut health during space flight.

Overall, low-gravity healthcare is a multidisciplinary endeavor across many medical fields and is necessary to protect the long-term health of astronauts, especially as various agencies aim for deeper exploratory space travel. In addition, the same medical breakthroughs have the potential to improve medical care for the general population too significantly.

More News to Read

comments

The rest is here:
Studying Astronaut Health Could Benefit Medicine for All - TrendinTech

Garrett Richards is cleared to throw off a mound, still has a chance to return this season – Los Angeles Times

The Angels hope to insert Garrett Richards into their rotation this season, but they are up against time. Eight weeks remain in this season, and Richards should require roughly six weeks to ramp up his pitching. Any setback, and hell run out of wiggle room.

After three weeks of playing catch from increasing distances, Richards visited a team physician late Thursday, who cleared the right-hander to throw off of a mound Friday. It will be Richards first time pitching since April 5, and it will start the unofficial six-week timeline.

If Richards pitched out of the bullpen, he could conceivably return sooner. But the Angels are not considering that option.

No plan with that, Angels manager Mike Scioscia said. I think hes a starter. You are thinking about his career too. I think it would be the wrong move to put him in the pen and put more stress on his arm than hes used to.

Richards, 29, has not pitched out of the bullpen since 2013. When he first reached the majors in 2011, he flitted between starting and relieving. The Angels are confident he is best-suited to starting.

But he has started only seven of the Angels last 271 games, dating to last season. On May 1, 2016, he exited a game with what proved to be a torn ulnar collateral ligament in his elbow. Instead of surgery, he opted to undergo stem-cell injections, which doctors said healed the ligament over time.

After a normal offseason, he felt cramping in his first start of this season, on April 5 in Oakland. Later in the week, he was diagnosed with nerve irritation in his right biceps.

For more than three months, he waited, lifting weights and taking regular strength tests. When his right biceps finally measured nearly the same as his left, he began playing catch.

Since May, Richards has understood he would miss most of the season. But he has believed a September return was possible, and it still is.

Short hops

Left fielder Cameron Maybin (sprained knee) will begin a rehab assignment with triple-A Salt Lake on Friday. Hell play again Saturday and could be activated as soon as Monday. Right fielder Kole Calhoun (strained hamstring) ran the bases without issue before Thursdays game and plans to play Friday. Third baseman Yunel Escobar (back strain) is on a similar track. Right-hander Alex Meyer played catch for the first time in two weeks. He has been on the disabled list with shoulder inflammation he reported after his last start. Right-hander Matt Shoemaker will throw a second bullpen session Saturday. He felt fine Thursday after throwing the day before.

pedro.moura@latimes.com

Follow Pedro Moura on Twitter @pedromoura

More here:
Garrett Richards is cleared to throw off a mound, still has a chance to return this season - Los Angeles Times

About Us – Stem Cell Medicine :: STEM CELL MEDICINE LTD.

COMPANY OVERVIEW Stem Cell Medicine's mission is to develop and commercialize cellular therapies in combination with pharmaceutical products to be used for tissue repair and for the treatment of inflammatory, immunological and neurological disorders.

The Company develops products from a number of tissue sources, such as adipose tissue stem cells for ischemic indications and from T cells for solid tumor-directed immunotherapies.

The Companys business plan calls for the engagement in collaboration with other companies, research institutions and medical centers. The aim of these collaborations is to shorten the industry's standard length of development cycles and expand the Companys technology and know-how in R&D, business development, marketing and management. Seeking partneships with companies that have products in development stages and early clinical development.

Stem Cell Medicine's facilities include state-of-the-art R&D laboratories and modern GMP manufacturing production rooms that, together with well-equipped analytical laboratories, provide an optimal environment for the development of products from inception to the clinic.

Additionally, the Company offers CMO services for products, including solid-form pharmaceuticals and injectibles,for use in clinical trials.

MISSION Stem Cell Medicine strives to facilitate the leap from existing stem cell R&D practices and technology and first-product development to pharmaceutical solutions by consolidating the existing stem cell know-how and expertise in Israel, Europe, USA and Asia (China). Stem Cell Medicine benefits from its privileged access to world class medical facilities, top research and the large pool of stem cell companies at various stages of development. THE FOUNDER Ehud Maroms career has circled around building companies that have a strong technical backbone in the fields of chemistry and life-sciences. Mr. Marom believes that in the future, stem cell product launches will continue to yield attractive returns. This outlook is based on a combination of the current known advancements in R&D, todays business and political/regulatory environment both in the U.S. and Israel, as well as the actual product launch successes we have seen to date. Mr. Marom had the privilege of playing a pivotal role in the early days of Gamida Cell, one of the leading Israeli biotech companies and a global leader in stem cell technologies and products. Mr. Marom led the development of the companys flagship product from pre-clinical to Phase III trials.

MANAGEMENT TEAM

Ehud Marom - Chairman & CEO Mr. Marom received his BSc in Chemical Engineering from the Technion Israel Institute of Technology with distinction. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he has held various senior positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals' API and Innovative divisions, where he was credited for his contribution to the market success of Teva; COO of Peptor Ltd; CEO of the Jerusalem-based biotechnology company, Gamida Cell, a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of Senior VP of Supply Chain at Makhteshim-Agan Group. In addition to his role as Chairman & CEO at Stem Cell Medicine, Mr. Marom also acts as Chairman & CEO of Mapi Pharma and Chairman of Pharma Two B.Dr. Frida Grynspan , VP R&D and Site ManagerDr. Grynspan has extensive experience in the areas of cellular therapeutics and protein chemistry. She served as VP R&D at CollPlant, Pluristem and Gamida Cell. Dr. Grynspan holds a PhD in Chemistry from the University of Illinois at Chicago and a post-doctoral degree from Harvard Medical School. Irit Zalayet - CFOMs. Zalayet CPA serves as Stem Cell Medicines CFO as of 2012. Prior to this Ms. Zalayet served as deputy CEO of Kesselman & Kesselman Trust Co. (1971) Ltd. and as a CPA at PwC Israel. Irit completed her Bachelors in Economics and Accounting and her M.A. in Law; both degrees are from The Bar-Ilan University. Ms. Zalayet also serves as the CFO of a related group party Pharma Two B. Ruth Reiss - Quality Assurance ManagerMs. Reiss joined Stem Cell Medicine in 2013. Prior to joining the company, she served as QA manager at Hy-Laboratories Ltd. She successfully led the company in its first FDA QP inspection in addition to GMP accreditation by the Israeli Ministry of Health. Ruth received her BSc in Agriculture from the Hebrew University in Jerusalem and a Business Management degree from the Open University of Israel.

Aviva Zyskind - Business Development Senior Associate Ms. Zyskind joined Stem Cell Medicine in 2014. Previously, she worked at KPMG in Israel where she founded the China Practice and worked as a member of the M&A team; and as International Project Coordinator at the Hisense R&D Center in China. She received her BA in Economics and Mandarin Chinese from Brandeis University and has lived and worked in China for three years.Dr. Yael Hayon - R&D Project ManagerDr. Hayon received her PhD in Neurobiology from Hebrew University Hadassah Medical Center and specializes in developing models of human disease and blood products within the fields of Stem Cells and Regenerative Medicine. Through the course of her work, she has registered a patent for clinical applications and presented her research in conferences around the world. Her findings have been published in five different journals. Prior to joining Stem Cell Medicine in 2014, Dr. Hayon has held a number of positions, including director of Cerebrovascular Research and Development at the Neurology and Hematology Departments and Deputy Director and Medical Advisor at the Blood Bank, Hadassah Medical Center.

Dr. Dotan Uzi - R&D Project Manager Dr. Uzi received his PhD in Medical Research from the Hebrew University Hadassah Medical Center and specializes in cellular metabolism and toxicity, gene therapy and human disease models as platforms for stem cell therapy. Prior to joining Stem Cell Medicine, he served as VP and Head of Research and Development at Clearance Ltd, and as Human Disease Model Consultant at BiolineRx. Dr. Uzi has published his work in leading journals and as a main author in a leading hepatology textbook. He has also received the Israel Association for the Study of the Liver's Award for Excellence twice.

Read more from the original source:
About Us - Stem Cell Medicine :: STEM CELL MEDICINE LTD.

Engineered Skin Cells Control Type 2 Diabetes in Mice: Study – Sioux City Journal

THURSDAY, Aug. 3, 2017 (HealthDay News) -- Scientists have created genetically altered skin cells that may control type 2 diabetes in lab mice. And they believe the general concept could someday be used to treat various diseases.

Using a combination of stem cells and "gene editing," the researchers created patches of skin cells that were able to release a hormone called GLP1 in a controlled manner.

The hormone, which is normally produced in the digestive tract, spurs the production of insulin -- the body's key regulator of blood sugar levels.

The scientists found that transplanting the engineered skin patches onto diabetic lab mice helped regulate their blood sugar levels over four months.

Xiaoyang Wu, a stem cell biologist at the University of Chicago, led the "proof of concept" study. He said it raises the possibility that "therapeutic skin grafts" could be used to treat a range of diseases -- from hemophilia to drug dependence.

Wu's team focused on type 2 diabetes in these initial experiments because it's a common condition.

However, a researcher not involved in the study doubted the usefulness of the approach for diabetes specifically.

People with type 2 diabetes already manage the disease with diet, exercise and medications -- including ones that target GLP1, said Juan Dominguez-Bendala.

Using high-tech gene therapy to get the same result seems unlikely, said Dominguez-Bendala, an associate professor at the University of Miami's Diabetes Research Institute.

"I don't see something like this coming to the clinic for diabetes," he said.

But Dominguez-Bendala also pointed to what's "cool" about the experiments.

Wu's team used a recently developed technology called CRISPR (pronounced "crisper") to create the skin patches. The technique, heralded as a major breakthrough in genetic engineering, allows scientists to make precision "edits" in DNA -- such as clipping a particular defect or inserting a gene at a specific location.

Before CRISPR, scientists could not control where an inserted gene would be integrated into the genome. It might end up in a "bad" location, Dominguez-Bendala explained, where it could, for example, "awaken" a tumor-promoting gene.

Wu and colleauges used CRISPR to make specific edits in GLP1, including one that allowed the gene to be turned "on" or "off" as needed, by using the antibiotic doxycycline.

The modified gene was inserted into mouse stem cells, which were then cultured into skin grafts in the lab. Finally, those grafts were transplanted onto lab mice.

The researchers found that when the mice were fed food with tiny amounts of doxycycline, the transplanted skin released GLP1 into the bloodstream. In turn, the animals' insulin levels rose and their blood sugar dipped.

The engineered skin also seemed to protect the mice from the ravages of a high-fat diet. When the mice were fed a fat-laden diet, along with doxycycline, they gained less weight versus normal mice given the same diet. They also showed less resistance to the effects of insulin, and lower blood sugar levels.

According to Wu, the study lays the groundwork for more research into using skin cells as a way to deliver "therapeutic proteins."

For instance, he said, skin cells could be engineered to provide an essential protein that is missing because of a genetic defect. As an example, he cited hemophilia -- a genetic disorder in which people lack a protein that allows the blood to clot properly.

Skin cells could be an ideal way to deliver such therapies, Wu said.

For one, the safety of skin grafts in humans is well-established, he pointed out. Since the 1970s, doctors have known how to harvest skin stem cells from burn victims, then use those cells to create lab-grown skin tissue.

Because the skin is generated from a patient's own stem cells, that minimizes the issue of an immune system attack on the tissue.

Dominguez-Bendala agreed that using skin cells has advantages. For one, he noted, the skin graft can be easily removed if something goes awry.

But a lot of work remains before therapeutic skin grafts could become a reality for any human disease. And research in animals doesn't always pan out in humans.

A next step, Wu said, is to see whether the skin grafts maintain their effects in lab mice over a longer period. The researchers will also monitor the animals for any immune system reactions against the GLP1 protein itself.

The findings were published online Aug. 3 in Cell Stem Cell.

The U.S. National Institutes of Health has a primer on gene therapy.

See the rest here:
Engineered Skin Cells Control Type 2 Diabetes in Mice: Study - Sioux City Journal

Qkine synchronises licensing deal – Global University Venturing

Qkine, a UK-based stem cell technology developer spun out from University of Cambridge, signed a key licensing agreement with the institutions tech transfer office Cambridge Enterprise on Tuesday.

The deal relates to Activin A production technology. Activin A, and related proteins, is one of the crucial elements in mimicking the environment in the human body and helps turn stem cells into specific cell types.

The technology was developed by co-founder Marko Hyvnen from the Department of Biochemistry.

Qkine was incorporated in November 2016 before securing a Pathfinder investment from Cambridge Enterprise the following month to facilitate setting up the business. It then began operations as an embedded company at the Department of Biochemistry in April.

Qkine aims to manufacture bioactive proteins that have applications in regenerative medicine and stem cell research. There is a need for this technology in a wide range of clinical areas, from disease modelling and drug screening to precision medicine.

MarkoHyvnen said: I have been providing growth factors to the Cambridge stem cell community for almost a decade.

Demand is growing from labs outside Cambridge and forming Qkine will allow us to focus on producing the highest quality cytokines for these scientists and establish a unique UK-based supplier of one of the enabling technologies for regenerative medicine, one of the priority areas for British manufacturing recently identified by the government.

Iain Thomas, head of life sciences at Cambridge Enterprise, said: Qkine is a great example of how opportunities are incubated in the university until the commercial time is right.

We are delighted that Qkine is taking this technology into the stem cell and regenerative medicine markets both of which are important and rapidly growing.

Read more here:
Qkine synchronises licensing deal - Global University Venturing

Cloning/Embryonic Stem Cells – National Human Genome …

Cloning/Embryonic Stem Cells

The term cloning is used by scientists to describe many different processes that involve making duplicates of biological material. In most cases, isolated genes or cells are duplicated for scientific study, and no new animal results. The experiment that led to the cloning of Dolly the sheep in 1997 was different: It used a cloning technique called somatic cell nuclear transfer and resulted in an animal that was a genetic twin -- although delayed in time -- of an adult sheep. This technique can also be used to produce an embryo from which cells called embryonic stem (ES) cells could be extracted to use in research into potential therapies for a wide variety of diseases.

Thus, in the past five years, much of the scientific and ethical debate about somatic cell nuclear transfer has focused on its two potential applications: 1) for reproductive purposes, i.e., to produce a child, or 2) for producing a source of ES cells for research.

The technique of transferring a nucleus from a somatic cell into an egg that produced Dolly was an extension of experiments that had been ongoing for over 40 years. In the simplest terms, the technique used to produce Dolly the sheep - somatic cell nuclear transplantation cloning - involves removing the nucleus of an egg and replacing it with the diploid nucleus of a somatic cell. Unlike sexual reproduction, during which a new organism is formed when the genetic material of the egg and sperm fuse, in nuclear transplantation cloning there is a single genetic "parent." This technique also differs from previous cloning techniques because it does not involve an existing embryo. Dolly is different because she is not genetically unique; when born she was genetically identical to an existing six-year-old ewe. Although the birth of Dolly was lauded as a success, in fact, the procedure has not been perfected and it is not yet clear whether Dolly will remain healthy or whether she is already experiencing subtle problems that might lead to serious diseases. Thus, the prospect of applying this technique in humans is troubling for scientific and safety reasons in addition to a variety of ethical reasons related to our ideas about the natural ordering of family and successive generations.

Several important concerns remain about the science and safety of nuclear transfer cloning using adult cells as the source of nuclei. To date, five mammalian species -- sheep, cattle, pigs, goats, and mice -- have been used extensively in reproductive cloning studies. Data from these experiments illustrate the problems involved. Typically, very few cloning attempts are successful. Many cloned animals die in utero, even at late stages or soon after birth, and those that survive frequently exhibit severe birth defects. In addition, female animals carrying cloned fetuses may face serious risks, including death from cloning-related complications.

An additional concern focuses on whether cellular aging will affect the ability of somatic cell nuclei to program normal development. As somatic cells divide they progressively age, and there is normally a defined number of cell divisions that can occur before senescence. Thus, the health effects for the resulting liveborn, having been created with an "aged" nucleus, are unknown. Recently it was reported that Dolly has arthritis, although it is not yet clear whether the five-and-a-half-year-old sheep is suffering from the condition as a result of the cloning process. And, scientists in Tokyo have shown that cloned mice die significantly earlier than those that are naturally conceived, raising an additional concern that the mutations that accumulate in somatic cells might affect nuclear transfer efficiency and lead to cancer and other diseases in offspring. Researchers working with clones of a Holstein cow say genetic programming errors may explain why so many cloned animals die, either as fetuses or newborns.

The announcement of Dolly sparked widespread speculation about a human child being created using somatic cell nuclear transfer. Much of the perceived fear that greeted this announcement centered on the misperception that a child or many children could be produced who would be identical to an already existing person. This fear is based on the idea of "genetic determinism" -- that genes alone determine all aspects of an individual -- and reflects the belief that a person's genes bear a simple relationship to the physical and psychological traits that compose that individual. Although genes play an essential role in the formation of physical and behavioral characteristics, each individual is, in fact, the result of a complex interaction between his or her genes and the environment within which he or she develops. Nonetheless, many of the concerns about cloning have focused on issues related to "playing God," interfering with the natural order of life, and somehow robbing a future individual of the right to a unique identity.

Several groups have concluded that reproductive cloning of human beings creates ethical and scientific risks that society should not tolerate. In 1997, the National Bioethics Advisory Commission recommended that it was morally unacceptable to attempt to create a child using somatic cell nuclear transfer cloning and suggested that a moratorium be imposed until safety of this technique could be assessed. The commission also cautioned against preempting the use of cloning technology for purposes unrelated to producing a liveborn child.

Similarly, in 2001 the National Academy of Sciences issued a report stating that the United States should ban human reproductive cloning aimed at creating a child because experience with reproductive cloning in animals suggests that the process would be dangerous for the woman, the fetus, and the newborn, and would likely fail. The report recommended that the proposed ban on human cloning should be reviewed within five years, but that it should be reconsidered "only if a new scientific review indicates that the procedures are likely to be safe and effective, and if a broad national dialogue on societal, religious and ethical issues suggests that reconsideration is warranted." The panel concluded that the scientific and medical considerations that justify a ban on human reproductive cloning at this time do not apply to nuclear transplantation to produce stem cells. Several other scientific and medical groups also have stated their opposition to the use of cloning for the purpose of producing a child.

The cloning debate was reopened with a new twist late in 1998, when two scientific reports were published regarding the successful isolation of human stem cells. Stem cells are unique and essential cells found in animals that are capable of continually reproducing themselves and renewing tissue throughout an individual organism's life. ES cells are the most versatile of all stem cells because they are less differentiated, or committed, to a particular function than adult stem cells. These cells have offered hope of new cures to debilitating and even fatal illness. Recent studies in mice and other animals have shown that ES cells can reduce symptoms of Parkinson's disease in mouse models, and work in other animal models and disease areas seems promising.

In the 1998 reports, ES cells were derived from in vitro embryos six to seven days old destined to be discarded by couples undergoing infertility treatments, and embryonic germ (EG) cells were obtained from cadaveric fetal tissue following elective abortion. A third report, appearing in the New York Times, claimed that a Massachusetts biotechnology company had fused a human cell with an enucleated cow egg, creating a hybrid clone that failed to progress beyond an early stage of development. This announcement served as a reminder that ES cells also could be derived from embryos created through somatic cell nuclear transfer, or cloning. In fact, several scientists believed that deriving ES cells in this manner is the most promising approach to developing treatments because the condition of in vitro fertilization (IVF) embryos stored over time is questionable and this type of cloning could overcome graft-host responses if resulting therapies were developed from the recipient's own DNA.

For those who believe that the embryo has the moral status of a person from the moment of conception, research or any other activity that would destroy it is wrong. For those who believe the human embryo deserves some measure of respect, but disagree that the respect due should equal that given to a fully formed human, it could be considered immoral not to use embryos that would otherwise be destroyed to develop potential cures for disease affecting millions of people. An additional concern related to public policy is whether federal funds should be used for research that some Americans find unethical.

Since 1996, Congress has prohibited researchers from using federal funds for human embryo research. In 1999, DHHS announced that it intended to fund research on human ES cells derived from embryos remaining after infertility treatments. This decision was based on an interpretation "that human embryonic stem cells are not a human embryo within the statutory definition" because "the cells do not have the capacity to develop into a human being even if transferred to the uterus, thus their destruction in the course of research would not constitute the destruction of an embryo." DHHS did not intend to fund research using stem cells derived from embryos created through cloning, although such efforts would be legal in the private sector.

In July 2001, the House of Representatives voted 265 to 162 to make any human cloning a criminal offense, including cloning to create an embryo for derivation of stem cells rather than to produce a child. In August 2002, President Bush, contending with a DHHS decision made during the Clinton administration, stated in a prime-time television address that federal support would be provided for research using a limited number of stem cell colonies already in existence (derived from leftover IVF embryos). Current bills before Congress would ban all forms of cloning outright, prohibit cloning for reproductive purposes, and impose a moratorium on cloning to derive stem cells for research, or prohibit cloning for reproductive purposes while allowing cloning for therapeutic purposes to go forward. As of late June, the Senate has taken no action. President Bush's Bioethics Council is expected to recommend the prohibition of reproductive cloning and a moratorium on therapeutic cloning later this summer.

Prepared by Kathi E. Hanna, M.S., Ph.D., Science and Health Policy Consultant

Last Reviewed: April 2006

Read the original here:
Cloning/Embryonic Stem Cells - National Human Genome ...

In a first, scientists rid human embryos of a potentially fatal gene mutation by editing their DNA – Los Angeles Times

Using a powerful gene-editing technique, scientists have rid human embryos of a mutation responsible for an inherited form of heart disease thats often deadly to healthy young athletes and adults in their prime.

The experiment marks the first time that scientists have altered the human genome to erase a disease-causing mutation not only from the DNA of the primary subject but from the genes of his or her progeny as well.

The controversial procedure, known as germ-line editing, was conducted at Oregon Health and Science University in Portland using human embryos expressly created for the purpose. It was reported Wednesday in the journal Nature.

Scientists ultimate goal is to fix gene mutations that lead to debilitating or fatal diseases, and to prevent the propagation of those mutations to future generations. Study leader Shoukhrat Mitalipov, a biologist at OHSU, said the new findings might correct genetic variants that can cause breast and ovarian cancer, cystic fibrosis and muscular dystrophy in those who inherit them.

But others fret that the technique may be used for less noble purposes, such as creating designer babies with desired traits like green eyes, an athletic build or an aptitude for mathematics.

In the United States, the Food and Drug Administration currently forbids any use of germ-line editing outside of a research setting.

But recent history has shown that people who want access to such techniques can find people willing to perform them in venues where theyre able to do so, said Jeffrey Kahn, who directs Johns Hopkins Universitys Berman Institute of Bioethics.

It will happen whether we discuss it or not, and we need to talk about these things before they happen, said Kahn. Thats now.

The new research comes less than six months after the National Academies of Science, Engineering and Medicine recommended that scientists limit their trials of human germ-line editing to diseases that could not be treated with reasonable alternatives at least for the time being.

In a bid to make the experiment relevant to the real-life problems faced by parents who carry disease-causing mutations, the researchers focused on a gene variant that causes inherited hypertrophic cardiomyopathy.

In this condition, a parent who carries one normal and one mutated copy of the MYBPC3 gene has a 50-50 chance of passing the faulty copy on to his or her offspring. If the child inherits the mutation, his or her heart muscle is likely to grow prematurely weak and stiff, causing heart failure and often early death.

In diseases in which one parent carries a gene like this, a couple will often seek the assistance of fertility doctors to minimize the risk of passing the mutation on to a child. A womans eggs and mans sperm meet in a lab using in vitro fertilization. Then specialists inspect the resulting embryos, cull the ones that have inherited an unwanted mutation, and transfer unaffected embryos into a womans uterus to be carried to term.

In the new research, researchers set out to test whether germ-line gene editing could make the process of choosing healthy embryos more effective and efficient by creating more of them.

It could. The targeted correction of a disease-causing gene carried by a single parent can potentially rescue a substantial portion of mutant human embryos, thus increasing the number of embryos available for transfer, the study authors reported.

The fix was made possible by a system known as CRISPR-Cas9, which has been sweeping through biology labs because it greatly simplifies the gene-editing process. It uses a small piece of RNA and an enzyme to snip out unwanted DNA and, if desired, replace it with something better.

If the process is found to be safe for use in fertility clinics, it could potentially decrease the number of cycles needed for people trying to have children free of genetic disease, said Dr. Paula Amato, a coauthor and professor of obstetrics and gynecology at Oregon Health and Science University.

The team encountered several scientific surprises along the way. Long-feared effects of germ-line editing, including collateral damage to off-target genetic sequences, scarcely materialized. And mosaicism, a phenomenon in which edited DNA appears in some but not all cells, was found to be minimal.

Mitalipov called these exciting and surprising moments. But he cautioned that there is room to improve the techniques for producing mutation-free embryos. Clinical trials would have to wait until the DNA editing showed a near-perfect level of efficiency and accuracy, he said, and could be limited by state and federal regulations.

There is still a long road ahead, said Mitalipov, who heads the Center for Embryonic Cell and Gene Therapy at OHSU.

Oregon Health & Science University

Human embryos developing into blastocysts after being injected with a gene-correcting enzyme and sperm carrying a mutation for a potentially fatal disease of the heart muscle.

Human embryos developing into blastocysts after being injected with a gene-correcting enzyme and sperm carrying a mutation for a potentially fatal disease of the heart muscle. (Oregon Health & Science University)

Oregon Health & Science University

Individual blastomeres within the early embryos two days after the co-injection. Each new cell in the developing embryos was uniformly free of the disease-causing mutation.

Individual blastomeres within the early embryos two days after the co-injection. Each new cell in the developing embryos was uniformly free of the disease-causing mutation. (Oregon Health & Science University)

Biologists, fertility doctors and ethicists have long anticipated that scientists would one day manipulate the DNA of human embryos. Now that the milestone has been reached, it drew a mix of praise and concern from experts in genetic medicine.

Dr. Richard O. Hynes, who co-chaired the National Academies report issued in February, called the new study very good science that advances the understanding of genetic repair on many fronts. Hynes, who was not involved with the research effort, said he was pleasantly surprised by the Oregon-based teams clever modifications and their outcomes.

Its likely to become feasible, technically not tomorrow, not next year, but in some foreseeable time. Less than a decade, Id say, said Hynes, a biologist and cancer researcher at MIT and the Howard Hughes Medical Institute.

UC Berkeley molecular and cell biologist Jennifer Doudna, one of pioneers of the CRISPR-Cas9 gene-editing system, said the new research highlights a prospective use of gene editing for one inherited disease and offers some insights into the process. But she questioned how broadly the experiments results would apply to other inherited diseases.

Doudna also said she does not believe using germ-line editing to improve efficiency at fertility clinics meets the criteria laid out by the National Academies of Sciences, which urged that the technology be explored only in cases in which its needed essentially as a last resort.

Already, 50% of embryos would be normal, she said. Why not just implant those?

Doudna said she feared that the new findings will encourage people to proceed down this road before the scientific and ethical implications of germ-line editing have been fully considered.

A large group of experts concluded that clinical use should not proceed until and unless theres broad societal consensus, and that just hasnt happened, she said. This study underscores the urgency of having those debates. Because its coming.

Kristyna Wentz-Graff/Oregon Health & Science University

Study leader Shoukhrat Mitalipov with coauthors Hong Ma, left, and Nuria Marti-Gutierrez.

Study leader Shoukhrat Mitalipov with coauthors Hong Ma, left, and Nuria Marti-Gutierrez. (Kristyna Wentz-Graff/Oregon Health & Science University)

The study authors a multinational team of geneticists, cardiologists, fertility experts and embryologists from OHSU, the Salk Institute in La Jolla, and labs in South Korea and China tested a number of innovations in an effort to improve the safety, efficiency and fidelity of gene editing. And most yielded promising results.

After retrieving eggs from 12 healthy female volunteers, the researchers simultaneously performed two steps that had never been combined in a lab: fertilizing the eggs with sperm and introducing the CRISPR-Cas9 repair machinery.

The resulting embryos took up the gene-editing program so efficiently and uniformly that, after five days of incubation, 72.4% of the 58 embryos tested were free of the MYBPC3 mutation. By comparison, when there was no attempt at gene editing, just 47.4% of embryos were free of the mutation responsible for the deadly heart condition.

The researchers believe their method prompted the embryos to rely on the healthy maternal copy of the gene as a model for fixing the MYBPC3 mutation, and not a repair template that used DNA from the sperm donors normal version of the gene. Only one of the 42 embryos used the introduced template for repair. The scientists contrasted this process to stem cells, which do use repair templates.

The embryos cells divided normally as they matured to the blastocyst stage, the point at which they would usually be ready for transfer to a womans uterus. After extensive testing, the embryos were used to make embryonic stem-cell lines, which are stored in liquid nitrogen and can be used in future research.

Researchers also noted that genetic mosaicism a concern raised by earlier experiments in gene-editing was virtually absent from 41 of the 42 embryos that were free of the disease-causing mutation.

MITs Hynes said such findings offer important insights into how human embryos grow, develop and respond to anomalies, and will help families facing infertility and inherited illnesses.

Human embryogenesis is clearly different from that of a mouse, which we know a lot about, Hynes said. That needs to be studied in human embryos, and theres no other way to do it.

At the same time, he downplayed fears that embryologists would soon tinker with such attributes as looks, personality traits and intelligence in human children.

Were not looking at designed babies around the corner not for a long time, he said.

melissa.healy@latimes.com

@LATMelissaHealy

MORE IN SCIENCE

The DNA of ancient Canaanites lives on in modern-day Lebanese, genetic analysis shows

You can predict how many blacks are killed by police by measuring the racism of whites, research finds

Is it Alzheimers or another dementia form? Why doctors need to distinguish and how they might do so

UPDATES:

3:50 p.m.: This story has been updated with comments from Jeffrey Kahn of Johns Hopkins Universitys Berman Institute of Bioethics.

This story was originally published at 10 a.m.

Read more here:
In a first, scientists rid human embryos of a potentially fatal gene mutation by editing their DNA - Los Angeles Times